Loading…
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $236M | $-8M | $-40M | $-16M | -11.4% | 15.4% | - |
| 2024 | $205M | $-10M | $-38M | $-41M | -10.7% | 37.6% | - |
| 2023 | $149M | $-8M | $-21M | $-44M | -5.6% | 21.6% | -1767.2% |
| 2022 | $122M | $-9M | $1M | $-32M | 0.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 122.29 | 148.73 | 204.73 | 236.35 |
| Cost Of Revenue | 31.63 | 37.48 | 56.13 | 63.69 |
| Gross Profit | 90.66 | 111.25 | 148.60 | 172.66 |
| Operating Expense | 112.45 | 137.02 | 178.12 | 201.66 |
| Operating Income | -21.79 | -25.77 | -29.52 | -29 |
| EBITDA | -8.69 | -8.38 | -10.44 | -7.88 |
| EBIT | -21.79 | -25.77 | -29.52 | -29 |
| Pretax Income | -3.69 | -21.31 | -41.93 | -39.19 |
| Tax Provision | -4.95 | -0.34 | -4.11 | 0.46 |
| Net Income | 1.26 | -20.97 | -37.82 | -39.65 |
| Net Income Common Stockholders | 1.24 | -20.97 | -37.82 | -39.65 |
| Total Expenses | 144.08 | 174.50 | 234.25 | 265.35 |
| Interest Expense | 2.42 | 0 | 0 | 0 |
| Research And Development | 8.45 | 10.89 | 11.03 | 9.10 |
| Selling General And Administration | 104 | 126.12 | 167.09 | 192.56 |
| Normalized EBITDA | -31.01 | -10.38 | -1.72 | 2.36 |
| Normalized Income | -16.38 | -22.94 | -29.96 | -31.56 |
| Basic EPS | 0.06 | -0.92 | -1.64 | -1.69 |
| Diluted EPS | 0.06 | -0.92 | -1.64 | -1.69 |
| Tax Effect Of Unusual Items | 4.69 | 0.03 | -0.85 | -2.15 |
| Tax Rate For Calcs | 0.21 | 0.02 | 0.10 | 0.21 |
| Total Unusual Items | 22.32 | 2 | -8.72 | -10.24 |
| Total Unusual Items Excluding Goodwill | 22.32 | 2 | -8.72 | -10.24 |
| Net Income From Continuing Operation Net Minority Interest | 1.26 | -20.97 | -37.82 | -39.65 |
| Reconciled Depreciation | 13.10 | 17.39 | 19.08 | 21.12 |
| Reconciled Cost Of Revenue | 31.63 | 37.48 | 56.13 | 63.69 |
| Net Interest Income | -2.42 | 0.20 | -2.62 | -6 |
| Net Income From Continuing And Discontinued Operation | 1.26 | -20.97 | -37.82 | -39.65 |
| Total Operating Income As Reported | -25.40 | -26.75 | -35.01 | -39.24 |
| Diluted Average Shares | 20.95 | 22.68 | 23.08 | 23.46 |
| Basic Average Shares | 20.70 | 22.68 | 23.08 | 23.46 |
| Diluted NI Availto Com Stockholders | 1.24 | -20.97 | -37.82 | -39.65 |
| Otherunder Preferred Stock Dividend | 0.02 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | 1.26 | -20.97 | -37.82 | -39.65 |
| Net Income Discontinuous Operations | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | 1.26 | -20.97 | -37.82 | -39.65 |
| Other Income Expense | 20.52 | 4.26 | -9.79 | -4.19 |
| Other Non Operating Income Expenses | -1.80 | 2.26 | -1.07 | 6.05 |
| Special Income Charges | 22.32 | 2 | -8.72 | -10.24 |
| Other Special Charges | 0 | 0 | 3.23 | 0 |
| Impairment Of Capital Assets | 3.61 | 0.98 | 1.84 | 4.64 |
| Restructuring And Mergern Acquisition | -25.93 | -2.98 | 3.65 | 5.60 |
| Net Non Operating Interest Income Expense | -2.42 | 0.20 | -2.62 | -6 |
| Total Other Finance Cost | 2.42 | -0.20 | 2.62 | 6 |
| Interest Expense Non Operating | 2.42 | 0 | 0 | 0 |
| Selling And Marketing Expense | 46.09 | 52.82 | 64.30 | 72.73 |
| General And Administrative Expense | 57.90 | 73.30 | 102.79 | 119.83 |
| Other Gand A | 57.90 | 73.30 | 102.79 | 119.83 |
| Operating Revenue | 122.29 | 148.73 | 204.73 | 236.35 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OrthoPediatrics Corp.this co. | KIDS | $376M | - | 1.06 | -11.4% | -53.45 |
| Weave Communications, Inc. | WEAV | $385M | - | 4.61 | -34.1% | -18.58 |
| Cerus Corporation | CERS | $385M | - | 5.75 | -24.1% | -52.90 |
| Niagen Bioscience, Inc. | NAGE | $381M | 23.80 | 4.97 | 22.7% | 21.23 |
| Puma Biotechnology, Inc. | PBYI | $381M | 12.26 |
| 2.89 |
| 23.9% |
| 6.57 |
| Viemed Healthcare, Inc. | VMD | $381M | 26.73 | 2.66 | 10.4% | 7.66 |
| Rocket Pharmaceuticals, Inc. | RCKT | $380M | - | 1.36 | -80.5% | -0.98 |
| NRC Health | NRC | $373M | 42.41 | 26.76 | 82.9% | 12.41 |
| The Oncology Institute, Inc. | TOI | $367M | - | -23.33 | 385.5% | -14.99 |
| Peer Median | - | 25.26 | 3.75 | 16.6% | 2.79 | |